Featured Event Investor Day 2019 Edificio de la Bolsa de Madrid, Plaza de la Lealtad 1, Madrid España Del 25/09/2019 to 26/09/2019 Financing This year, Asebio organizes this event along with the Spanish Alternative Stock Market-BME, the Platform of...
Oryzon Genomics has strengthened its patent portfolio with the European grant of protectio... 01/10/2025 Financing Oryzon Genomics has strengthened its patent portfolio with the European grant of protection for iadademstat in... Partners - Oryzon Genomics
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financin... 10/09/2025 Healthcare Access to innovation Financing Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational... Partners - Asabys Partners
CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X ... 09/09/2025 Healthcare Access to innovation Financing CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Partners - CONNECTA THERAPEUTICS
Integra Therapeutics secures €10.7 million investment round to advance development of FiCA... 08/09/2025 Healthcare Advanced therapies Financing The investment combines funds from new investors like the EIC Fund (European Commission) and CDTI Innvierte (Government... Partners - Integra Therapeutics S.L.
Agarose resins made in Spain celebrate a quarter of a century 03/09/2025 Financing Corporate Agarose Bead Technologies (ABT), compañía pionera en el desarrollo de resinas de agarosa, celebra su 25 aniversario... Partners - Agarose Bead Technologies (ABT)
Critical Path Management in Biomedical Startups: A Framework for Early Implementation 03/09/2025 Financing Talento Digitalization The biomedical industry's current funding landscape demands a fundamental shift in how emerging companies approach their... Partners - VIVA IN VITRO
Inveready successfully closes Inveready Innvierte Biotech II, its second life sciences fun... 22/07/2025 Financing Corporate Inveready completes its third venture capital fund with a 4.3x return on capital invested by shareholders Partners - Inveready
